Radiotherapy Vs. Surgery for Esophageal Cancer: A Cost-Effectiveness Study

Why It Matters

The cost‑effectiveness evidence supports shifting treatment strategies toward less invasive, cheaper radiotherapy, potentially easing financial strain on China's oncology system and improving patient access.

Key Takeaways

• Radiotherapy cheaper than surgery for ESCC in China.
• Markov model shows comparable survival with lower complications.
• Real‑world data enhances applicability of cost‑effectiveness results.
• Findings could reshape Chinese oncology guidelines and resource allocation.
• Patient‑centered decision making benefits from cost transparency.

Pulse Analysis

Esophageal squamous cell carcinoma (ESCC) is a growing public‑health challenge across developing nations, with China bearing a disproportionate share of cases. As incidence climbs, health systems confront the dual pressures of delivering high‑quality oncology care while containing spiraling expenditures. Economic evaluations, therefore, have become essential tools for policymakers seeking to allocate limited resources efficiently and to ensure equitable access to life‑saving treatments.

The study by Xu, Liu and Chen leverages a Markov simulation built on extensive real‑world patient records, offering a granular view of treatment pathways that randomized trials often miss. By incorporating direct costs—surgical fees, radiotherapy sessions, hospitalization—and indirect factors such as lost productivity and long‑term follow‑up, the model quantifies the total economic burden of each modality. Real‑world data enhances external validity, reflecting diverse patient comorbidities and practice variations, while the Markov framework captures transitions between health states over a lifetime horizon, delivering robust cost‑effectiveness ratios.

Findings that radiotherapy can match surgical outcomes at lower cost have immediate implications for Chinese clinical guidelines and reimbursement policies. Health insurers may prioritize non‑invasive options, and hospitals could reallocate operating‑room resources toward expanding radiotherapy capacity. Moreover, transparent cost information empowers patients to engage in shared decision‑making, aligning treatment choices with personal financial circumstances. The methodology also serves as a template for other middle‑income economies grappling with similar oncology budget constraints, underscoring the strategic value of integrating economic modeling into cancer care planning. Continued monitoring and adaptation will be crucial as technology evolves and cost structures shift.